GlassScriptPhysician profile
Brian J Allar
NPI 1841813813
$5,000.80
in general payments reported to CMS, 2019-2025
29 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $741 · 2022: $1,411 · 2023: $1,857 · 2024: $874 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605 · Education: $228 · Consulting Fee: $15.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.41 |
| Education | $227.99 |
| Consulting Fee | $15.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $629.71 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $548.67 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $523.66 | 2021-2024 | Brilinta, Farxiga |
| Janssen Pharmaceuticals, INC | $508.14 | 2021-2023 | Xarelto |
| Amgen INC. | $495.84 | 2022-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $440.33 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $316.36 | 2022-2024 | Eliquis, Camzyos |
| Actelion Pharmaceuticals US, INC. | $269.04 | 2022-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.71 | 2023-2024 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $152.26 | 2022-2023 | Arcalyst |
| Pfizer INC. | $139.00 | 2022-2024 | |
| Edwards Lifesciences Corporation | $101.23 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $85.45 | 2021-2023 | Watchman Access System |
| Baxter Healthcare | $77.10 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $70.80 | 2023 | Onpattro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $66.54 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $65.35 | 2021-2023 | |
| Kestra Medical Technology Services, INC. | $53.61 | 2023-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $50.58 | 2023-2024 | |
| Novo Nordisk INC | $40.17 | 2024 | Rybelsus, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $36.48 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $28.20 | 2024 | |
| Bardy Diagnostics, INC. | $24.80 | 2022 | |
| Abiomed | $23.64 | 2025 | |
| Cordis US Corp. | $21.59 | 2025 | Mynx Control |
| Amarin Pharma, INC. | $16.93 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2021 | |
| Daiichi Sankyo INC. | $13.96 | 2021 | |
| Medtronic, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Allar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.